Companies › ORIC Pharmaceuticals
3 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Rinzimetostat NAMPT inhibitor | NAMPT | Phase 3 | Metastatic Castration Resistant Prostate Cancer | Mar 2028 |
| ORIC-114 Tyrosine kinase inhibitor targeting EGFR and HER2 | – | Phase 1 | Solid Tumors | Dec 2026 |
| ORIC-944 ORIC-944 (mechanism not specified in registry text) | – | Phase 1 | Metastatic Prostate Cancer | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06816992 | ORIC-114 | Phase 1 | Solid Tumors | Oncology | Dec 2026 |
| NCT05315700 | ORIC-114 | Phase 1 | Solid Tumors | Oncology | Jun 2027 |
| NCT05413421 | ORIC-944 | Phase 1 | Metastatic Prostate Cancer | Oncology | Jun 2027 |
| NCT07723248 | Rinzimetostat | Phase 3 | Metastatic Castration Resistant Prostate Cancer | Oncology | Mar 2028 |
Cash and short-term investments of $265m on 2026-06-30; operating cash outflow about $130m a year; runway about 24 months at that burn, to Jul 2028; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
ArriVent BioPharma Cogent Biosciences Olema Pharmaceuticals Immunome Day One Biopharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.